Literature DB >> 23380134

Risk factors associated with diabetic macular edema.

Thuan M Diep1, Irena Tsui.   

Abstract

Diabetic macular edema (DME) is the most common cause of vision loss in patients with type 1 and type 2 diabetes. Glycemic control, hypertension, and dyslipidemia are known to be important risks factors for DME. In addition, nephropathy, anemia, sleep apnea, glitazone usage, and pregnancy are also important modifiable risk factors. It is important for physicians of different subspecialties to work together and understand multiple aspects of DME and diabetic healthcare. Published by Elsevier Ireland Ltd.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23380134     DOI： 10.1016/j.diabres.2013.01.011

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN： 0168-8227            Impact factor:   5.602


  15 in total

1.  Application of higher-order spectra for automated grading of diabetic maculopathy.

Authors:  Muthu Rama Krishnan Mookiah; U Rajendra Acharya; Vinod Chandran; Roshan Joy Martis; Jen Hong Tan; Joel E W Koh; Chua Kuang Chua; Louis Tong; Augustinus Laude
Journal:  Med Biol Eng Comput       Date:  2015-04-18       Impact factor: 2.602

2.  Impact of insulin treatment in diabetic macular edema therapy in type 2 diabetes.

Authors:  Simone Matsuda; Tiffany Tam; Rishi P Singh; Peter K Kaiser; Daniel Petkovsek; Maria Teresa Zanella; Justis P Ehlers
Journal:  Can J Diabetes       Date:  2014-10-22       Impact factor: 4.190

3.  Optical coherence tomography findings in patients with transfusion-dependent β-thalassemia.

Authors:  Sezaneh Haghpanah; Omid Reza Zekavat; Sanaz Safaei; Mohammad Ali Ashraf; Shirin Parand; Hossein Ashraf
Journal:  BMC Ophthalmol       Date:  2022-06-24       Impact factor: 2.086

4.  Natural history of diabetic macular edema and factors predicting outcomes in sham-treated patients (MEAD study).

Authors:  Young Hee Yoon; David S Boyer; Raj K Maturi; Francesco Bandello; Rubens Belfort; Albert J Augustin; Xiao-Yan Li; Zhanying Bai; Yehia Hashad
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-10-25       Impact factor: 3.117

Review 5.  Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group.

Authors:  Winfried M Amoaku; Faruque Ghanchi; Clare Bailey; Sanjiv Banerjee; Somnath Banerjee; Louise Downey; Richard Gale; Robin Hamilton; Kamlesh Khunti; Esther Posner; Fahd Quhill; Stephen Robinson; Roopa Setty; Dawn Sim; Deepali Varma; Hemal Mehta
Journal:  Eye (Lond)       Date:  2020-06       Impact factor: 3.775

Review 6.  Updates in the management of diabetic macular edema.

Authors:  Christopher Mathew; Anastasia Yunirakasiwi; Srinivasan Sanjay
Journal:  J Diabetes Res       Date:  2015-04-23       Impact factor: 4.011

7.  Clinical Characteristics of Patients with Newly Diagnosed Diabetic Macular Edema in Turkey: A Real-Life Registry Study-TURK-DEM.

Authors:  Bora Eldem; Sengul Ozdek; Ali Osman Saatci; Emin Ozmert; Esat Ulay; Gulsah Nomak
Journal:  J Ophthalmol       Date:  2017-02-19       Impact factor: 1.909

8.  Systemic and ocular diseases associated with the development of diabetic macular edema among Japanese patients with diabetes mellitus.

Authors:  Atsuki Kume; Kenji Kashiwagi
Journal:  BMC Ophthalmol       Date:  2020-07-29       Impact factor: 2.209

9.  Lower Hemoglobin Concentration Is Associated with Retinal Ischemia and the Severity of Diabetic Retinopathy in Type 2 Diabetes.

Authors:  Alicia Traveset; Esther Rubinat; Emilio Ortega; Nuria Alcubierre; Beatriz Vazquez; Marta Hernández; Carmen Jurjo; Ramon Espinet; Juan Antonio Ezpeleta; Didac Mauricio
Journal:  J Diabetes Res       Date:  2016-04-20       Impact factor: 4.011

10.  Safety and Efficacy of Ranibizumab and Luseogliflozin Combination Therapy in Patients with Diabetic Macular Edema: Protocol for a Multicenter, Open-Label Randomized Controlled Trial.

Authors:  Ryoichi Ishibashi; Yoko Takatsuna; Masaya Koshizaka; Tomoaki Tatsumi; Sho Takahashi; Kengo Nagashima; Noriko Asaumi; Miyuki Arai; Fumio Shimada; Kaori Tachibana; Yoshihiro Watanabe; Ko Ishikawa; Akiko Hoshino; Kyohei Yamamoto; Mariko Kubota-Taniai; Takafumi Mayama; Shuichi Yamamoto; Koutaro Yokote
Journal:  Diabetes Ther       Date:  2020-06-15       Impact factor: 2.945
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.